Meeting
2022 ASCO Annual Meeting
Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors.
Authors
Rodabe Navroze Amaria
The University of Texas MD Anderson Cancer Center, Houston, TX
Rodabe Navroze Amaria , David J. Vining , Scott Kopetz , Michael J. Overman , Milind M. Javle , Mara Antonoff , Ching-Wei D. Tzeng , Robert A. Wolff , Shubham Pant , Kathryn Lito , Kelly M. Rangel , Louis Wilson , Bryan M. Fellman , Cara L. Haymaker , Ying Yuan , Marie-Andree Forget , Patrick Hwu , Chantale Bernatchez , Amir A. Jazaeri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03610490
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2536)
DOI
10.1200/JCO.2022.40.16_suppl.2536
Abstract #
2536
Poster Bd #
191
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
First Author: Amir A. Jazaeri
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee
Poster
2024 ASCO Annual Meeting
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
First Author: Jiayong Liu
Poster
2019 ASCO Annual Meeting
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
First Author: Amod Sarnaik